Covered recipient · General Payments record
JASON ASHER DAMSKER
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$11,997.32
- Reported across 267 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $4,425.50 | 3 |
| Food and Beverage | $1,259.26 | 53 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $1,837.50 | 1 |
| GENZYME CORPORATION | $1,648.00 | 1 |
| Daiichi Sankyo Inc. | $977.32 | 4 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $173.10 | 7 |
| Janssen Biotech, Inc. | $152.96 | 6 |
| PFIZER INC. | $117.90 | 6 |
| Regeneron Healthcare Solutions, Inc. | $98.96 | 2 |
| Genentech USA, Inc. | $71.88 | 3 |
| GlaxoSmithKline, LLC. | $59.98 | 3 |
| ARRAY BIOPHARMA INC | $55.21 | 2 |
| Genmab U.S., Inc. | $53.79 | 2 |
| PROGENICS PHARMACEUTICALS, INC. | $52.45 | 2 |
| Mirati Therapeutics, Inc. | $44.77 | 2 |
| E.R. Squibb & Sons, L.L.C. | $41.49 | 2 |
| Merck Sharp & Dohme Corporation | $27.97 | 1 |
| Gilead Sciences, Inc. | $25.82 | 1 |
| Lilly USA, LLC | $24.94 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $24.48 | 1 |
| SERVIER PHARMACEUTICALS LLC | $24.19 | 1 |
| Incyte Corporation | $23.99 | 1 |
| Celgene Corporation | $23.48 | 1 |
| MorphoSys, US Inc. | $22.82 | 1 |
| Pharmacosmos Therapeutics Inc. | $22.51 | 1 |
| Apellis Pharmaceuticals, Inc. | $22.45 | 1 |
| Stemline Therapeutics Inc. | $21.61 | 1 |
| Acerta Pharma LLC | $18.84 | 1 |
| ABBVIE INC. | $16.35 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (56)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.